Reasons for William Hutchinson’s Shares Unload of Western Asset Corporate Loan Fu (TLI)’s Stock; 4 Analysts Are Bullish Entellus Medical, Inc. (ENTL) Last Week

Entellus Medical, Inc. (NASDAQ:ENTL) Logo

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. As per Friday, December 8, the company rating was downgraded by William Blair. Deutsche Bank initiated the shares of ENTL in report on Thursday, October 6 with “Buy” rating. As per Sunday, August 9, the company rating was maintained by Canaccord Genuity. The rating was maintained by Piper Jaffray on Tuesday, September 29 with “”. The firm earned “Buy” rating on Monday, August 21 by Piper Jaffray. The stock has “Buy” rating by BTIG Research on Tuesday, June 14. The firm earned “Hold” rating on Monday, October 16 by Canaccord Genuity. See Entellus Medical, Inc. (NASDAQ:ENTL) latest ratings:

08/12/2017 Broker: William Blair Rating: Hold Downgrade
16/10/2017 Broker: Canaccord Genuity Rating: Hold New Target: $17.0 Maintain

It closed at $24 lastly. It is down 0.00% since April 11, 2017 and is . It has underperformed by 11.55% the S&P500.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $617.48 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

A public report filed with the DC-based SEC on 11-04-2018 made public that William Hutchinson, the director of Western Asset Corporate Loan Fund Inc, ‘s company sold 8,226 shares. With average cost per share of $10.4 the transaction’s amount is $85,897 US Dollars. Today, William Hutchinson owns 1,774 shares which are precisely 0.02% of the Company’s total market capitalization.

Entellus Medical, Inc. (NASDAQ:ENTL) Ratings Chart